Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Blast cell crisis"'
Autor:
Mia E. Geurts, Nicholas Derfler, John Ngo, Christian I. Wade, Kyle Couperus, Cody J. Couperus-Mashewske
Publikováno v:
Clinical Practice and Cases in Emergency Medicine, Vol 4, Iss 3 (2020)
Clinical Practice and Cases in Emergency Medicine
Clinical Practice and Cases in Emergency Medicine
Author(s): Wade, Christian I.; Couperus-Mashewske, Cody J.; Geurts, Mia E.; Derfler, Nicholas; Ngo, John; Couperus, Kyle S. | Abstract: Introduction: Symptomatic leukostasis is an exceptionally atypical presentation of blast crisis; and when coupled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8b707cf3e39ecb9310ec34d29d09582
https://escholarship.org/uc/item/7581435h
https://escholarship.org/uc/item/7581435h
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Osman Ilhan, Rıdvan Ali, Zafer Baslar, Ibrahim C. Haznedaroglu, Orhan Ayyildiz, Diyar Z. Akkaynak, Ugur Ozbek, Leylagül Kaynar, Mehmet Sönmez, Demet Aydin, Akif Selim Yavuz, Bülent Ündar, Ilkiz M. Dag, Mustafa Pehlivan, Güray Saydam, Birol Guvenc, Olga Meltem Akay, Simten Dagdas
PubMed ID: 27501474
Objective: Nilotinib is a BCR-ABL1 tyrosine kinase inhibitor approved for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP). This study was the first prospective evaluation of the efficacy and
Objective: Nilotinib is a BCR-ABL1 tyrosine kinase inhibitor approved for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP). This study was the first prospective evaluation of the efficacy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef7978eceb03118408c2e8f7f3666597
https://hdl.handle.net/20.500.12605/18279
https://hdl.handle.net/20.500.12605/18279
Autor:
Fahir Özkalemkaş, Rıdvan Ali, Mutlu Karkucak, Murat Pekgöz, Hulya Ozturk Nazlioglu, Serhat Korkmaz, Tahsin Yakut, Ahmet Tunali, Ferah Budak, Vildan Ozkocaman, Tulay Ozcelik
Imatinib has shown significant clinical and cytogenetic success in the treatment of chronic myeloid leukemia. Although resistance has been observed in a proportion of patients, sudden blastic crisis is a rare event during imatinib therapy. We describ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91eea59e5b394d8c7d6463fb7766132e
http://hdl.handle.net/11452/26745
http://hdl.handle.net/11452/26745
Autor:
Mehmet H. Koseoglu, Hulki Meltem Sönmez, Ekrem Muftuoglu, Gurhan Kadikoylu, Süleyman Demir, Orhan Ayyildiz, Zahit Bolaman
Publikováno v:
Haematologia. 32(1)
Fourteen patients with blastic phase chronic myelogenous leukemia received combination chemotherapy with mitoxantrone 5 mg/m2 intravenously daily for 3 days, cytosine arabinoside 100 mg/m2 intravenously over 2 hours bid for 7 days and high dose methy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f90932862c6640e3652355e3f72548f7
https://pubmed.ncbi.nlm.nih.gov/12243555
https://pubmed.ncbi.nlm.nih.gov/12243555
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.